Valuation: Geron Corporation

Market Cap 597M 533M 489M 445M 834M 56.51B 851M 5.84B 2.35B 29.83B 2.24B 2.19B 94.21B P/E 2026 *
-21.1x
P/E 2027 * 14.1x
Enterprise Value 597M 533M 489M 445M 834M 56.51B 851M 5.84B 2.35B 29.83B 2.24B 2.19B 94.21B EV / Sales 2026 *
2.54x
EV / Sales 2027 * 1.75x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day+1.07%
1 week-19.21%
Current month+3.88%
1 month-22.58%
3 months-27.98%
6 months-41.20%
Current year-29.61%
1 week 0.84
Extreme 0.84
1.05
1 month 0.84
Extreme 0.84
1.26
Current year 0.84
Extreme 0.84
2.01
1 year 0.84
Extreme 0.84
2.01
3 years 0.84
Extreme 0.84
5.34
5 years 0.84
Extreme 0.84
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 55 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Free

Director

6,351 0.0010%
30/06/26 Free

Director

6,103 0.0010%
20/05/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
+1.39%-19.21%-26.26%-47.80% 597M
-2.37%-5.03%+39.49%+62.39% 62.23B
+0.94%+1.07%+11.47%+69.93% 54.92B
+0.31%+1.76%+19.99%+96.60% 55.26B
-0.83%-5.54%+19.39%+35.69% 42.59B
-3.26%-2.59%+16.36%+98.45% 41.08B
+1.74%+2.32%+219.80%+789.69% 40.33B
+0.45%+23.22%+98.07%+82.82% 33.12B
+0.21%+1.05%+14.81%+46.96% 32.61B
+0.05%+17.12%-42.35%+337.07% 23.98B
Average -0.24%+1.83%+37.08%+157.18% 38.67B
Weighted average by Cap. -0.46%+2.71%+44.62%+162.40%

Financials

2026 *2027 *
Net sales 235M 210M 193M 175M 329M 22.28B 335M 2.3B 928M 11.76B 883M 864M 37.15B 341M 304M 279M 254M 477M 32.29B 486M 3.34B 1.35B 17.04B 1.28B 1.25B 53.83B
Net income -25.41M -22.69M -20.82M -18.94M -35.5M -2.41B -36.21M -249M -100M -1.27B -95.36M -93.33M -4.01B 37.75M 33.7M 30.93M 28.13M 52.74M 3.57B 53.79M 369M 149M 1.89B 142M 139M 5.96B
Net Debt - -
Projected Income Statement - Annual - Geron Corporation
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
03/11/26 $0.9291 +3.88% 13,797,240
30/10/26 $0.8944 -5.47% 18,809,282
29/10/26 $0.9462 -2.30% 32,350,409
28/10/26 $0.9685 -15.78% 81,724,765
27/10/26 $1.150 0.00% 6,709,313
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Geron Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.9291USD
Average target price
3.625USD
Spread / Average Target
+290.16%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Geron Corporation
  1. Stock Market
  2. Stocks
  3. GERN Stock